Levodopa has been the mainstay of treatment for Parkinson’s disease (PD) for more than 40 years. During this time, researchers have strived to optimize levodopa formulations to minimize side effects, enhance central nervous system (CNS) bioavailability, and achieve stable therapeutic plasma levels. Current strategies include concomitant treatment with inhibitors of dopa decarboxylase (DDC) and catechol-O-methyltransferase (COMT) to prolong the peripheral levodopa half-life and increase CNS bioavailability. Levodopa combined with DDC inhibition is the current standard method of delivering levodopa for symptomatic treatment of PD. Recent research suggests that continuous dopaminergic stimulation that more closely approximates physiological stimulation may delay or prevent the development of motor fluctuations (‘wearing off’) and dyskinesias. Strategies currently being used to achieve more continuous dopaminergic stimulation include the combination of an oral levodopa/DDC inhibitor with a COMT inhibitor and the enteral infusion of a levodopa gel formulation. Attempts are underway to develop oral and transdermal very long-acting levodopa preparations.

Keywords:
Levodopa, Levodopa, historical perspective, Levodopa therapy, complications, Parkinson’s disease, Dopa decarboxylase inhibition, Catechol-O-methyltransferase inhibition
1.
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415–455.
2.
Lloyd KG, Hornykiewicz O: Parkinson’s disease: activity of L-dopa decarboxylase in discrete brain regions. Science 1970;170:1213.
3.
Fahn S, Libsch LR, Cutler RW: Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson’s disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971;14:427– 455.
4.
Lang AE: The progression of Parkinson disease: a hypothesis. Neurology 2007;68:948–952.
5.
Hornykiewicz O: Biochemical aspects of Parkinson’s disease. Neurology 1998;51:S2–S9.
6.
Kish SJ, Shannak K, Hornykiewicz O: Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876–880.
7.
Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002;41:261–309.
8.
Oldfield V, Keating GM, Perry CM: Rasagiline: a review of its use in the management of Parkinson’s disease. Drugs 2007;67:1725–1747.
9.
Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ: Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983–995.
10.
Hornykiewicz O: L-Dopa: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 2002;23:65–70.
11.
Montagu KA: Catechol compounds in rat tissues and in brains of different animals. Nature 1957;180:244–245.
12.
Weil-Malherbe H, Bone AD: Intracellular distribution of catecholamines in the brain. Nature 1957;180:1050–1051.
13.
Carlsson A, Lindqvist M, Magnusson T: 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200.
14.
Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takegada M, Nishinuma K: Distribution of catechol compounds in human brain. Biochim Biophys Acta 1959;32:586–587.
15.
Foley P: The L-dopa story revisited. Further surprises to be expected? J Neural Transm Suppl 2000;60:1–20.
16.
Ehringer H, Hornykiewicz O: Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disord 1998;4:53–57.
17.
Birkmayer W, Hornykiewicz O: The effect of L-3,4-dihydroxyphenylalanine (L-dopa) on akinesia in parkinsonism. Parkinsonism Relat Disord 1998;4:59–60.
18.
McGeer PL, Zeldowicz LR: Administration of dihydroxyphenylalanine to parkinsonian patients. Can Med Assoc J 1964;90:463–466.
19.
Bertler A, Rosengren E: Possible role of brain dopamine. Pharmacol Rev 1966;18:769–773.
20.
Cotzias GC, Van Woert MH, Schiffer LM: Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374–379.
21.
Cotzias GC: L-Dopa for Parkinsonism. N Engl J Med 1968;278:630.
22.
Cotzias GC, Papavasiliou PS, Vanwoert MH, Sakamoto A: Melanogenesis and extrapyramidal diseases. Fed Proc 1964;23:713–718.
23.
Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM: Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343–354.
24.
Lloyd KG, Davidson L, Hornykiewicz O: The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975;195:453–464.
25.
Cotzias GC, Papavasiliou PS, Gellene R: Modification of Parkinsonism – chronic treatment with L-dopa. N Engl J Med 1969;280:337–345.
26.
Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448–458.
27.
Fahn S: Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs. later L-dopa. Arch Neurol 1999;56:529–535.
28.
Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA: Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002;59:408–413.
29.
Gunal DI, Nurichalichi K, Tuncer N, Bekiroglu N, Aktan S: The clinical profile of nonmotor fluctuations in Parkinson’s disease patients. Can J Neurol Sci 2002;29:61–64.
30.
Olanow CW, Obeso JA, Stocchi F: Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol 2006;2:382–392.
31.
Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW: The evolution and origin of motor complications in Parkinson’s disease. Neurology 2000;55:S13–S20.
32.
Blanchet PJ, Grondin R, Bedard PJ, Shiosaki K, Britton DR: Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. Eur J Pharmacol 1996;309:13–20.
33.
Olanow CW, Obeso JA, Stocchi F: Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677–687.
34.
Stocchi F, Ruggieri S, Vacca L, Olanow CW: Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 2002;125:2058–2066.
35.
Nutt JG, Fellman JH: Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35–49.
36.
Jankovic J: Levodopa strengths and weaknesses. Neurology 2002;58:S19–S32.
37.
Pletscher A, DaPrada M: Pharmacotherapy of Parkinson’s disease: research from 1960 to 1991. Acta Neurol Scand Suppl 1993;146:26–31.
38.
Cedarbaum JM: Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141–178.
39.
Tolosa E, Marti MJ, Valldeoriola F, Molinuevo JL: History of levodopa and dopamine agonists in Parkinson’s disease treatment. Neurology 1998;50:S2–S10.
40.
Markham C, Diamond SG, Treciokas LJ: Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol 1974;31:128–133.
41.
Lieberman A, Goodgold A, Jonas S, Leibowitz M: Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson’s disease. Neurology 1975;25:911–916.
42.
LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, Schlick P: Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39:45–53.
43.
Koller WC, Hutton JT, Tolosa E, Capilldeo R: Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53:1012–1019.
44.
Hammerstad JP, Woodward WR, Nutt JG, Gancher ST, Block GA, Cyhan G: Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Clin Neuropharmacol 1994;17:429–434.
45.
Block G, Liss C, Reines S, Irr J, Nibbelink D: Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23–27.
46.
Mannisto PT, Kaakkola S: New selective COMT inhibitors: useful adjuncts for Parkinson’s disease? Trends Pharmacol Sci 1989;10:54–56.
47.
Lee ES, Chen H, King J, Charlton C: The role of 3-O-methyldopa in the side effects of L-dopa. Neurochem Res 2008;33:401–411.
48.
Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E: Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II). Mov Disord 1997;12:928–934.
49.
Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G: Catechol-O-methyltransferase inhibition with tolcapone reduces the ‘wearing off’ phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421–428.
50.
Adler CH, Singer C, O’Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K: Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998;55:1089–1095.
51.
Fenelon G, Gimenez-Roldan S, Montastruc JL, Bermejo F, Durif F, Bourdeix I, Pere JJ, Galiano L, Schadrack J: Efficacy and tolerability of entacapone in patients with Parkinson’s disease treated with levodopa plus a dopamine agonist and experiencing wearing- off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm 2003;110:239–251.
52.
Mizuno Y, Kanazawa I, Kuno S, Yanagisawa N, Yamamoto M, Kondo T: Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. Mov Disord 2007;22:75–80.
53.
Grandas F, Hernandez B: Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson’s disease patients: the effects of an early therapeutic intervention. Eur J Neurol 2007;14:282–289.
54.
Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M; NOMESAFE Study Group: The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease. Eur J Neurol 2003;10:137–146.
55.
Gershanik O, Emre M, Bernhard G, Sauer D: Efficacy and safety of levodopa with entacapone in Parkinson’s disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:963–971.
56.
Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I: Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001;45:111–118.
57.
Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN: Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685–2688.
58.
Limousin P, Pollak P, Gervason-Tournier CL, Hommel M, Perret JE: Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson’s disease. Lancet 1993;341:1605.
59.
Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP, Gordin A: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913–919.
60.
Entacapone to Tolcapone Switch Study Investigators: Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord 2007;22:14–19.
61.
Borges N: Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 2005;4:69–73.
62.
Olanow CW, Watkins PB: Tolcapone: an efficacy and safety review. Clin Neuropharmacol 2007;30:287–294.
63.
Parkinson Study Group: Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997;42:747–755.
64.
Rinne UK, Larsen JP, Siden A, Worm-Petersen J; Nomecomt Study Group: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309–1314.
65.
Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M: Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen Study). Acta Neurol Scand 2002;105:245–255.
66.
Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo-controlled, double-blind, six-month study. J Neurol Neurosurg Psychiatry 2003;74:1071–1079.
67.
Smith LA, Jackson MJ, Al Barghouthy G, Rose S, Kuoppamäki M, Olanow W, Jenner P: Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005;20:306–314.
68.
Hauser RA: Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004;62:S64–S71.
69.
Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A: Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. Mov Disord 2008. [Epub ahead of print].
70.
Schrag A: Entacapone in the treatment of Parkinson’s disease. Lancet Neurol 2005;4:366–370.
71.
Stocchi F: Optimising levodopa therapy for the management of Parkinson’s disease. J Neurol 2005;252(suppl 4):IV43–IV48.
72.
Nyholm D: Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev Neurother 2006;6:1403–1411.
73.
Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal FM, Lopiano L, Pezzoli G: Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 2007;22:1145–1149.
74.
Syed N, Murphy J, Zimmerman T Jr, Mark MH, Sage JI: Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson’s disease. Mov Disord 1998;13:336–338.
75.
Goole J, Deleuze P, Vanderbist F, Amighi K: New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer. Eur J Pharm Biopharm 2008;68:310–318.
76.
Di Stefano A, Sozio P, Cerasa LS: Antiparkinson prodrugs. Molecules 2008;13:46–68.
77.
Priano L, Gasco MR, Mauro A: Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006;23:357–375.
78.
Kankkunen T, Huupponen I, Lahtinen K, Sundell M, Ekman K, Kontturi K, Hirvonen J: Improved stability and release control of levodopa and metaraminol using ion-exchange fibers and transdermal iontophoresis. Eur J Pharm Sci 2002;16:273–280.
79.
Bonnet AM: Involvement of non-dopaminergic pathways in Parkinson’s disease: pathophysiology and therapeutic implications. CNS Drugs 2000;13:351–364.
© 2009 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.